An observational two-center case-control study exploring the clinical impact of double-carbapenem use in a population of critically il patients with severe carbapenem-resistant Klebsiella pneumoniae infection

Inclusion Criteria:

1. age ≥ 18 years;
2. ICU admission between November 2012 and December 2015;
3. documented CR-Kp invasive infection;
4. targeted antibiotic therapy lasting ≥ 72 hours

Exclusion Criteria

1. Klebsiella infection, susceptible to carbapenems
2. Duration of antimicrobial therapy less than 72 hours
3. Data not completely available from the electronically medical chart

Critically ill patients with severe CR-Kp infection